Table 3.
Univariate analysis for factors affecting the cosmetic outcome
| Factor | No. of patients (%) | Cosmetic outcome by BCCT.core |
p-value | |
|---|---|---|---|---|
| Excellent or good (%) | Fair or bad (%) | |||
| Age (yr) | 54.8±9.3 | 57.5±6.9 | 0.601 | |
| Menopause | 31 (61) | 24 (47) | 5 (10) | 0.723 |
| Histology | ||||
| DCIS | 9 (18) | 7 (14) | 2 (4) | 0.589 |
| LCIS | 1 (2) | 1 (2) | 0 | |
| IDC | 39 (76) | 33 (65) | 6 (12) | |
| ILC | 2 (4) | 1 (2) | 1 (2) | |
| Location of tumora) | ||||
| UOQ | 29 (57) | 24 (47) | 5 (10) | 0.763 |
| UIQ | 12 (24) | 11 (22) | 1 (2) | |
| LOQ | 4 (8) | 3 (7) | 1 (2) | |
| LIQ | 2 (4) | 2 (4) | 0 | |
| Central | 3 (6) | 2 (4) | 1 (2) | |
| Longest diameter of tumor (cm) | 1.6±0.8 | 2.0±1.5 | 0.635 | |
| Tumor volume (cm3) | 3.4±4.4 | 8.8±18.6 | 0.561 | |
| Re-excision rate | 46 (90) | 38 (75) | 8 (16) | 0.884 |
| Nipple excision rate | 3 (6) | 2 (4) | 1 (2) | |
| Axillary lymph node dissection rate | 14 (27) | 11 (22) | 3 (6) | 0.663 |
| Excised tissue volume (cm3) | 64.0±35.8 | 95.3±54.4 | 0.067 | |
| Excised skin area (cm2) | 6.1±3.1 | 14.1±9.8 | 0.294 | |
| Chemotherapy regimen | ||||
| Not done | 22 (43) | 18 (35) | 4 (8) | 0.217 |
| AC±D | 18 (35) | 16 (31) | 2 (4) | |
| CMF | 7 (14) | 4 (8) | 3 (6) | |
| Others | 4 (8) | 4 (8) | 0 | |
| Herceptin rate | 3 (6) | 2 (4) | 1 (2) | 0.463 |
| Hormonal therapy rate | 11 (22) | 9 (18) | 2 (4) | 0.958 |
| Length of tangential field (cm) | 18.1±1.7 | 18.4±1.6 | 0.790 | |
| Width of tangential field (cm) | 8.0±1.1 | 8.6±0.7 | 0.034 | |
| Dmax (%) | 110.2±1.5 | 111.6±1.7 | 0.019 | |
| Electron boost | ||||
| Not done | 8 (16) | 7 (14) | 1 (2) | 0.542 |
| 9-10 Gy | 39 (76) | 31 (61) | 8 (16) | |
| 14.4-16 Gy | 4 (8) | 4 (8) | 0 | |
| Supraclavicular field rate | 41 (80) | 33 (65) | 8 (16) | 0.479 |
DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in situ; IDC, infiltrative ductal carcinoma; ILC, infiltrative lobular carcinoma; UOQ, upper outer quadrant; UIQ, upper inner quadrant; LOQ, lower outer quadrant; LIQ, lower inner quadrant; AC, cyclophosphamide and doxorubicin; D, docetaxel; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; Dmax, maximum dose within breast.
a)
Available data only.